A Study of HTD1801 in Healthy Subjects

NCT03099603 | Completed Phase 1 DMC

• 1 other identifier: 1801.PCT002
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

This is a randomized, double blind, single center, ascending single dose study to evaluate the safety, tolerability, and PK of HTD1801.

Conditions

Primary Sclerosing Cholangitis

Outcome Measures

Primary Outcomes (1)

• Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs) after single dose

  Incidence, severity and causality of AEs and SAEs

  up to Day 30

Secondary Outcomes (5)

• HTD1801 plasma concentration levels after single dose

  96 hours

• Pharmacokinetics (PK) of HTD1801 in plasma after single dose - peak plasma concentration (Cmax)

  96 hours

• PK of HTD1801 in plasma after single dose - area under the plasma concentration vs. time curve (AUC)

  96 hours

• PK of HTD1801 in plasma after single dose - time to peak plasma concentration (Tmax)

  96 hours

• PK of HTD1801 in plasma after single dose - half life (T1/2)

  96 hours

Study Arms (4)

0.5g

PLACEBO COMPARATOR

single dose of placebo to 2 healthy subjects or 0.5g HTD1801 to 6 healthy subjects

Drug: HTD1801

1.0g

PLACEBO COMPARATOR

single dose of placebo to 2 healthy subjects or 1.0g HTD1801 to 6 healthy subjects

Drug: HTD1801

2.0g

PLACEBO COMPARATOR

single dose of placebo to 2 healthy subjects or 2.0g HTD1801 to 6 healthy subjects

Drug: HTD1801

4.0g

PLACEBO COMPARATOR

single dose of placebo to 2 healthy subjects or 4.0g HTD1801 to 6 healthy subjects

Drug: HTD1801

Interventions

HTD1801 DRUG

A small molecular compound for the treatment of primary sclerosing cholangitis

0.5g; 1.0g; 2.0g; 4.0g

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Age ≥18 to ≤ 50 years
• Body mass index (BMI) ≥18.0 to ≤ 30.0 kg/m2
• Current non-user of any nicotine containing products (\>6 months)
• Females must be non-pregnant and non-lactating, and either surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or post-menopausal for ≥12 months. The site will try to retrieve medical records to document the sterility, however, the absence of records will not exclude screening the participant. If medical records cannot be obtained, serum and urine pregnancy testing will be conducted. Postmenopausal status will be confirmed through testing of FSH levels ≥ 40 IU/mL at screening for amenorrheic female participants \<50 years of age.
• Males must be surgically sterile (\>30 days since vasectomy with no viable sperm), abstinent or if engaged in sexual relations with a child-bearing potential, the participant and his partner must be using an acceptable, highly effective, contraceptive method from Screening and for a period of 60 days after the last dose of Study Drug. Acceptable methods of contraception are the use of condoms and an effective contraceptive for the female partner that includes: surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception, or intrauterine contraception/device). The Principal Investigator will assess the adequacy of methods of contraception on a case-by-case basis.
• Ability to provide written informed consent.

You may not qualify if:

• Participation in an investigational drug study within 30 days prior to dosing or 5 half-lives within the last dose of investigational product whichever is longer.
• Current use of any prescription or over-the-counter (OTC) medications, including herbal products and supplements, within 14 days prior to Day 1 or 5 half-lives, whichever is longer. \[Use of ≤2 g per day of paracetamol (acetaminophen) is allowed prior to and during the study at Investigator discretion. The reason for use must be listed either in the subject's baseline information or as an adverse event.\]
• Any use of non-steroid anti-inflammatory drugs (NSAIDs) within 7 days prior to dosing.
• History of any serious adverse reaction or hypersensitivity to any of the product components.
• Use of parenterally administered proteins or antibodies within 12 weeks of screening. (Note: Influenza vaccine will be allowed)
• Glucose-6-phosphate dehydrogenase(G6PD) deficiency.
• History of weight loss \> 5% in the 8 weeks prior to screening.
• History of any active infection, other than mild viral illness, within 30 days prior to dosing.
• History of alcohol or illicit drug abuse as judged by the Investigator within approximately 1 year
• Use of any nicotine-containing product within 6 months prior to Screening or at any time during the study and follow-up as confirmed by urine cotinine screening.
• Presence of clinically significant medical history, physical, laboratory, or ECG findings that, in the opinion of the Investigator, may potentially compromise the safety of the subject, or interfere with any aspect of study conduct or interpretation of results.

Sponsors & Collaborators

• HighTide Biopharma Pty Ltd: lead

Study Sites (1)

Nucleus Network Limited

Melbourne, Victoria, 3004, Australia

Location

MeSH Terms

Conditions

Cholangitis, Sclerosing

Condition Hierarchy (Ancestors)

Cholangitis; Bile Duct Diseases; Biliary Tract Diseases; Digestive System Diseases

Study Officials

• Janet Wong, Doctor

  Nucleus Network Ltd

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 14, 2017
• First Posted: April 4, 2017
• Study Start: March 24, 2017
• Primary Completion: July 11, 2017
• Study Completion: October 3, 2017
• Last Updated: July 27, 2020

Record last verified: 2020-07

Data Sharing

• IPD Sharing: Will not share

Locations

AU (1)